Phase I/II Clinical Trial Stem Cell Gene Therapy in RAG1-Deficient SCID

  • STATUS
    Recruiting
  • End date
    Apr 1, 2024
  • participants needed
    5
  • sponsor
    Leiden University Medical Center
Updated on 4 April 2021

Summary

This study is a prospective, non-randomized, open-label, two-centre phase I/II intervention study designed to treat children up to 24 months of age with RAG1-deficient SCID with an indication for allogeneic hematopoietic stem cell transplantation but lacking an HLA-matched donor. The study involves infusion of autologous CD34+ cells transduced with the pCCL.MND.coRAG1.wpre lentiviral vector (hereafter called RAG1 LV CD34+ cells) in five patients with RAG1-deficient SCID.

Description

Severe combined immunodeficiency (SCID) is a genetically heterogeneous life-threatening disease characterized by severely impaired T cell development with or without impaired natural killer (NK) and B cell development or function depending on the genetic defect. Mutations in recombination activating genes 1 and 2 (RAG1 and RAG2) represent about 20% of all types of SCID. SCID is a paediatric emergency since it leads to severe and recurrent infections often in combination with protracted diarrhoea and failure to thrive. When left untreated, it is usually fatal within the first year of life. Currently, the only curative treatment option for RAG-deficient SCID is allogeneic hematopoietic stem cell transplantation (HSCT). Despite improvements in HSCT in recent years, this treatment is associated with serious potential complications like graft-versus-host disease which results in an unfavourable outcome, particularly in patients who lack a human leukocyte antigen (HLA)-matched donor. In recent years, gene therapy based on transplantation of autologous gene-corrected hematopoietic stem cells (HSC) has evolved as an effective and safe therapeutic option for X-linked and ADA-deficient forms of SCID. We have recently demonstrated that gene therapy using lentiviral (LV) self-inactivating (SIN) vectors expressing codon-optimized human RAG1 in a mouse model for RAG1-deficient SCID effectively restores T and B cell development and function. In this phase I/II explorative intervention study feasibility, safety and efficacy of gene therapy using gene-corrected autologous CD34+-selected mobilized peripheral blood or bone marrow cells will be investigated in patients with RAG1-deficient SCID with an indication for allogeneic HSCT but lacking an human leukocyte antigen (HLA)-matched donor.

Details
Condition Severe Combined Immunodeficiency Due to Complete RAG1 and/or RAG2 Deficiency, Severe Combined Immunodeficiency Due to Complete RAG1 and/or RAG2 Deficiency, Severe Combined Immunodeficiency Due to RAG1 Deficiency
Treatment Gene therapy, Gene therapy
Clinical Study IdentifierNCT04797260
SponsorLeiden University Medical Center
Last Modified on4 April 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

RAG1-deficient SCID as confirmed by genetic analysis
Peripheral blood T cells < 300/L and/or nave T cells < 1/L
Age < 2 years
Age at least 8 weeks by the time of busulfan and fludarabine administration
Lack of an available HLA-matched donor (HLA-identical sibling or 10/10 (A, B, C, DR, DQ) allele-matched (un)related donor)
Signed informed consent (parental or guardian)
Able to return to the study centre for follow-up (per protocol) during the 2-year study and the 15-year long-term off study review

Exclusion Criteria

Availability of an HLA-matched donor (HLA-identical sibling or 10/10 (A, B, C, DR, DQ) allele-matched (un)related donor)
RAG1 deficiency with peripheral blood T cells > 300/L and/or nave T cells > 1/L
Omenn syndrome
Previous allogeneic HSCT
Significant organ dysfunction/co-morbidity (including but not limited to the ones listed below)
Mechanical ventilation
Shortening fraction on echocardiogram <25%
Renal failure defined as dialysis dependence
Uncontrolled seizure disorder
any other medical condition which, in the opinion of the treating physician, would interfere with the good conduction of the clinical trial (e.g. contraindications for stem cell harvest or administration of conditioning medication)
Human immunodeficiency virus (HIV) infection or Human T-cell Leukemia Virus (HTLV) infection
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note